First-Line Sacituzumab Govitecan Plus Pembrolizumab Shows Promising Early Activity in NSCLC

In a preliminary analysis of the phase 2 EVOKE-02 trial, the investigational combination regimen showed an objective response rate of 56% in previously untreated patients with metastatic non–small cell lung cancer (NSCLC).

Related Keywords

Byoung Chul Cho ,Yonsei University College Of Medicine ,International Association ,Lung Cancer ,Chul Cho ,Medical Oncology ,Yonsei Cancer Center ,Yonsei University College ,Bill Grossman ,Evoke 02 ,Nsclc ,Sacituzumab Govitecan ,Pembrolizumab ,